Peroxiredoxin I expression in oral cancer: a potential new tumor marker

被引：101

作者：

Yanagawa, T

Iwasa, S

Ishii, T

Tabuchi, K

Yusa, H

Onizawa, K

Omura, K

Harada, H

Suzuki, H

Yoshida, H

机构：

[1] Univ Tsukuba, Inst Clin Med, Dept Oral & Maxillofacial Surg, Tsukuba, Ibaraki 3058575, Japan

[2] Univ Tsukuba, Inst Basic Med Sci, Dept Pathol, Tsukuba, Ibaraki 305, Japan

[3] Univ Tsukuba, Inst Basic Med Sci, Dept Biochem, Tsukuba, Ibaraki 305, Japan

[4] Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Mol Genet, Dallas, TX USA

[5] Chiba Canc Ctr Hosp, Div Head & Neck Surg, Chiba, Japan

来源：

CANCER LETTERS | 2000年 / 156卷 / 01期

关键词：

peroxiredoxin; proliferation associated gene; proliferating cell nuclear antigen; squamous cell carcinoma; MSP23; natural killer enhancing factor;

D O I：

10.1016/S0304-3835(00)00434-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This study investigates the applicability of the novel antioxidant protein, peroxiredoxin (Prx) I as a marker for tumor status in oral squamous cell carcinoma (SCC). Samples from 53 patients with SCC in the oral cavity were examined by immunohistochemistry. Correlations between the expression level of Prx I and proliferating cell nuclear antigen (PCNA), the clinical features of tumors, and their histopathological classifications were statistically analyzed. Cases exhibiting low Prx I expression level included significantly more with larger tumor mass cases (T-category, P = 0.004), positive lymph node metastasis (N-category, P = 0.015), advanced stage (P = 0.002), and poorly differentiated cells (P = 0.020). There was no significant difference between Prx I expression and the other indices. (C) 2000 Published by Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：27 / 35

页数：9

共 41 条

[1]

AALTOMAA S, 1992, ANTICANCER RES, V12, P1281

[2]

ALSHENEBER IF, 1993, CANCER, V71, P1954, DOI 10.1002/1097-0142(19930315)71:6<1954::AID-CNCR2820710605>3.0.CO

[3]

2-#

[4]

BOYLE JO, 1993, CANCER RES, V53, P4477